Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study

NCT06003218 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06003218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06003218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study
Lead sponsor
Peking University First Hospital
Phase
Not applicable
Overall status
Completed
Start date
October 16, 2023
Completion date
September 28, 2024
Enrollment
88 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dexmedetomidine, esketamine, liver cancer, radiofrequency ablation